Editas medicine stock price.

Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...

Editas medicine stock price. Things To Know About Editas medicine stock price.

Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Editas Medicine is a CRISPR company based out of Cambridge, Massachusetts, working "to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines " At the ...Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Find the latest Editas Medicine, Inc. (8EM.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.

Editas Medicine stock price target cut to $35 from $80 at Truist Nov. 18, 2022 at 7:08 a.m. ET by Tomi Kilgore Editas Medicine started at neutral with $18 stock price target at …Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...

Nov 24, 2023 · Get a real-time Editas Medicine, Inc. (EDIT) stock price quote with breaking news, financials, statistics, charts and more. Find out the current price target and stock forecast for Editas Medicine ... Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85 ...By contrast, Bluebird and Editas shares both fell by over 50% over the first six months of 2022, while CRISPR's stock price stumbled by a noteworthy 20% during the first half of the year. Image ...Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1.3%. A change of -13% or more over 5 trading days is a 6% likelihood ...

The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53. During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01. The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks.

3 Nov 2023 ... ... Editas Medicine's financial status. The company holds a market cap of 684.13M USD, reflecting its size in terms of market value. The price ...

The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ...Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 8.55% so far this month. During the month of April, Editas Medicine Inc’s stock price has reached a high of $7.21 and a low of $6.45. Over the last year, Editas Medicine Inc has hit prices as high as $20.04 and as low as $6.70. Year to date, Editas ...This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a …CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and …

Research Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. ... The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$10 ...intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 12/01/2023 the closing price of the Editas …Editas Medicine Inc stock price (EDIT) NASDAQ: EDIT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53. During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01. The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks.Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company …Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company …

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …

Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.EDIT Stock 12 Months Forecast. $12.60. (43.51% Upside) Based on 12 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $12.60 with a high forecast of $19.00 and a low forecast of $7.00. The average price target represents a 43.51% change from the last price of $8.78.Dec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. North American Morning Briefing : Stock Futures, -2- Oct. 02: DJ Stifel Upgrades Editas Medicine to Buy From Hold, Adjusts Price Target to $17 From $9 Sep. 29: MT Editas Medicine Jumps 8% in Premarket Activity Friday ... Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating Aug. 03: MT Editas …Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST Zacks

Shares of Editas Medicine (EDIT 3.76%) were tumbling 13% lower this week as of the market close on Thursday, ... Stock Advisor list price is $199 per year. Join Stock Advisor

Jun 20, 2023 · On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ... Editas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EDIT updated stock price target summary.Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksApr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... Shares of Editas Medicine (EDIT 3.76%) were tumbling 13% lower this week as of the market close on Thursday, ... Stock Advisor list price is $199 per year. Join Stock AdvisorEditas Medicine Announces Pricing of Offering of Common Stock 06-15 - 2 views Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial EDIT-301 was well-tolerated and demonstrated a safety profile consi 06-09 - 1 viewCAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Medicine Matters Sharing successes, challenges and daily happenings in the Department of Medicine Medicine Matters is a place to share department news in a way that is accessible to all and discuss issues and challenges important to our fac...

Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksApr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... Historical daily share price chart and data for Editas Medicine since 2016 adjusted for splits and dividends. The latest closing stock price for Editas Medicine as of November 20, …Instagram:https://instagram. free stock scannerscolombia bolsa de valoressimulation tradingconventional loan lenders Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. vanguard real estatebiogen stocks Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ... stocks td bank Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...